About Sterkem Pharma Private Limited
Data last updated:
Sterkem Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 28 March 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2002PTC135324. Its GSTIN is 27AAGCS2781K1ZX (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹2 Lakh and a paid-up capital of ₹2 Lakh. It is led by directors including Heena Mayank Patel and Ajit Naginbhai Desai.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹12.83 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net loss of ₹9.28 Lakh (net margin -0.7%) and EBITDA of ₹5,799 (EBITDA margin 0%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 3% over five years.
The company has about 119 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Ster Chem and Sterkem Pharma. As per MCA filings, the company has open charges of ₹11 Lakh on record. Court records list 18 cases involving the company, including 13 filed by the company and 5 filed against it; 11 cases are pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sterkempharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressS/3 Khira Indl Estate B M Bhargoankar Road, Santacruz West, Mumbai, Maharashtra, India – 400054
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Sterkem Pharma Private Limited
The main business activity of Sterkem Pharma is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Sterkem Pharma Private Limited FY 2025 filings available
Sterkem Pharma Private Limited reported revenue of ₹12.83 Cr (up 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Sterkem Pharma Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 2% growth in the latest year. EBITDA fell 100% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Sterkem Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹5,799 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹9.28 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Sterkem Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -0.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sterkem Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Sterkem Pharma Private Limited
Sterkem Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sn2 Asymmetrix Private Limited | ₹12.88 Cr (FY 2024) | •••• | •••• | -3.0% | •••• | Dist, Telangana, India |
| Calren Care Lifesciences Private Limited | ₹12.87 Cr (FY 2025) | •••• | •••• | 25.0% | •••• | Hyderabad, Telangana, India |
| Dr. Balram Healthcare Private Limited | ₹12.87 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Kozhikode, Kerala, India |
| Sagry Health Care Private Limited | ₹12.85 Cr (FY 2025) | •••• | •••• | -14.0% | •••• | Kanpur, Uttar Pradesh, India |
| Sindhuja Hydrocarbons Private Limited | ₹12.84 Cr (FY 2024) | •••• | •••• | 142.0% | •••• | Ahmedabad, Gujarat, India |
| Sterkem Pharma Private Limited this company | ₹12.83 Cr (FY 2025) | •••• | •••• | 2.0% | •••• | Mumbai, Maharashtra, India |
| Larivin Pharma Private Limited | ₹12.83 Cr (FY 2024) | •••• | •••• | •••• | Chennai, Tamil Nadu, India | |
| Three Dots Life Science Private Limited | ₹12.83 Cr (FY 2025) | •••• | •••• | 21.0% | •••• | Patna, Bihar, India |
| Regoshin Healthcare Private Limited | ₹12.81 Cr (FY 2024) | •••• | •••• | 25.0% | •••• | New Delhi, Delhi, India |
| Uniwend Medicals Pvt Ltd | ₹12.81 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Quilon, Kerala, India |
| Integrity Formulations Private Limited | ₹12.8 Cr (FY 2025) | •••• | •••• | -34.0% | •••• | Vadodara, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Sterkem Pharma by revenue in the Pharma industry (Pharma Retail and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Sterkem Pharma Private Limited
Sterkem Pharma Private Limited is audited by SANJAY M. DESAI & CO for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SANJAY M. DESAI & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Sterkem Pharma Private Limited
Sterkem Pharma has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Heena Mayank Patel Also directs: E M Pharmaceuticals Private Limited | Director | 01 Apr 2015 | 11 Years 6 Months | Current |
| Ajit Naginbhai Desai Also directs: E M Pharmaceuticals Private Limited | Director | 28 Mar 2002 | 24 Years 6 Months | Current |
| Sheela Harish Merchant | Director | 01 Sep 2025 | 1 Years 1 Months | Current |
Ownership and Shareholding of Sterkem Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Sterkem Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Nov 2023 | Hdfc Bank Limited | ₹11 Lakh | Open |
Total charge records: 1 View all charges
Legal Cases of Sterkem Pharma Private Limited
Sterkem Pharma Private Limited has 18 court cases on record: 13 filed by Sterkem Pharma, 5 filed against it. 11 cases are pending and 7 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 14 | 2 | 9 |
| High courts | 4 | 3 | 2 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gurugram, Haryana | Cheque dishonour complaint | Filed by the company against Elfin Drugs Private Limited | Pending |
| District court, East, Delhi | Cheque dishonour complaint | Filed by the company against Taksa Lifescience Private Limited | Pending |
| District court, East, Delhi | Cheque dishonour complaint | Filed by the company against Biomax Biotechnics Private Limited | Pending |
| District court, East, Delhi | Cheque dishonour complaint | Filed by the company against Dipna Pharmachem Limited | Pending |
| District court, East, Delhi | Cheque dishonour complaint | Filed by the company against Alaric Life Sciences Private Limited | Pending |
Full case history
All 18 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Sterkem Pharma Private Limited
Sterkem Pharma Private Limited has 2 MSME Form 1 returns on record between 2021 and 2022, listing 150 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 7)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Primus Pharmaceuticals | •••• | •••• | •••• |
| Integrated Laboratories Private Limited | •••• | •••• | •••• |
| Sayora Pharma Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Knox Life Science | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 2 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Sterkem Pharma Private Limited
Sterkem Pharma operates two associated brands: Ster Chem and Sterkem Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Ster Chem is a CDMO specializing in the manufacturing of active pharmaceutical ingredients. | sterchem.com | |
| Pharmaceutical marketing of anti-arthritic drugs, analgesics, and nutritional supplements in healthcare. | sterkempharma.com |
Employees and EPFO Compliance at Sterkem Pharma Private Limited
Sterkem Pharma Private Limited has a workforce of 119 employees as of Apr 03, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sterkem Pharma Private Limited
Sterkem Pharma Private Limited has 6 board changes on record since 2002: 3 appointments and 3 cessations. The latest: Sheela Harish Merchant was appointed as Director on 01 Sep 2025.
Credit Ratings, Litigation & Regulatory Alerts for Sterkem Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sterkem Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sterkem Pharma Private Limited
Sterkem Pharma has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAGCS2781K1ZX | Maharashtra | Active | 01 Jul 2017 |
| 24AAGCS2781K1Z3 | Gujarat | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sterkem Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sterkem Pharma Private Limited
Sterkem Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 28 March 2002 (24+ years old) and is registered under CIN U51909MH2002PTC135324.
Sterkem Pharma reported revenue of ₹12.83 Cr for FY 2025 (up 2% YoY).
Sterkem Pharma has 3 current directors:
- Heena Mayank Patel - Director
- Ajit Naginbhai Desai - Director
- Sheela Harish Merchant - Director
Sterkem Pharma reported a net loss of ₹9.28 Lakh (net margin -0.7%) and EBITDA of ₹5,799 (EBITDA margin 0%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Sterkem Pharma is 4% over three years and 3% over five years. In the latest year (FY 2025) revenue rose 2%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Sterkem Pharma is 27AAGCS2781K1ZX, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 24AAGCS2781K1Z3 (Gujarat).
The CIN (Corporate Identification Number) of Sterkem Pharma is U51909MH2002PTC135324. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sterkem Pharma has 18 court cases on record: 13 filed by the company and 5 filed against it. 11 are pending. Most are in the district courts.
Sterkem Pharma was incorporated on 28 March 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Sterkem Pharma by revenue are Sn2 Asymmetrix Private Limited, Calren Care Lifesciences Private Limited, Dr. Balram Healthcare Private Limited, Sagry Health Care Private Limited, Sindhuja Hydrocarbons Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution).
Sheela Harish Merchant was appointed as Director on 01 Sep 2025. Jayantilal Lallubhai Patel ceased to be Director on 01 Jul 2015. Heena Mayank Patel was appointed as Director on 01 Apr 2015. Sterkem Pharma has 6 board changes on record in total.
Sterkem Pharma has 2 MSME Form 1 returns on record between 2021 and 2022, listing 150 overdue payments to 7 micro and small suppliers. The latest return was filed on 09 May 2022.